Bio-Connect
Chemical Structure
Chemical Structure
Chemical Structure

Bufalin [465-21-4]

Research Use Only
AG-CN2-0533
AdipoGen Life Sciences
CAS Number465-21-4
Product group Chemicals
Estimated Purity>98%
Molecular Weight386.5
Sign in to order and to see your custom pricing.
Large volume orders?
Order with a bulk request

Overview

  • Supplier
    AdipoGen Life Sciences
  • Product Name
    Bufalin
  • Delivery Days Customer
    10
  • ADR Class
    6.1
  • CAS Number
    465-21-4
  • Certification
    Research Use Only
  • Estimated Purity
    >98%
  • Hazard Information
    Danger,Excepted quantity
  • Molecular Formula
    C24H34O4
  • Molecular Weight
    386.5
  • Scientific Description
    Bufalin is a cardiotonic steroid with anaesthetic, blood pressure stimulatory and respiratory activities. It is a potent Na+/K+-ATPase transporter inhibitor (Kd = 42, 45, and 40nM for the alpha1, alpha2, and alpha3 subunits, respectively). Bufalin has anticancer effects in a variety of cancer cell lines both in vitro and in vivo. It inhibits cancer cell proliferation, induces cell cycle arrest, induces apoptosis and autophagy, inhibits angiogenesis and neovascularization, induces cell differentiation, inhibits cancer metastasis and invasion, and enhances chemotherapeutic drug sensitivity through multiple kinase targets and also the Na+/K+-ATPase transporter. It also inhibits proteins of the steroid receptor coactivator family, such as SRC-1 and SRC-3 at 5nM. Bufalin has anti-inflammatory effects by modulating nuclear factor-kappaB (NF-kappaB) signaling and down-regulating inflammatory-related genes such as cyclooxygenases, lipoxygenases, inducible nitric oxide synthase (iNOS), and thereby decrease nitric oxide and prostaglandin E2 (PGE2) production. - Chemical. CAS: 465-21-4. Formula: C24H34O4. MW: 386.5. Isolated from venenum bufonis. Bufalin is a cardiotonic steroid with anaesthetic, blood pressure stimulatory and respiratory activities. It is a potent Na+/K+-ATPase transporter inhibitor (Kd = 42, 45, and 40nM for the alpha1, alpha2, and alpha3 subunits, respectively). Bufalin has anticancer effects in a variety of cancer cell lines both in vitro and in vivo. It inhibits cancer cell proliferation, induces cell cycle arrest, induces apoptosis and autophagy, inhibits angiogenesis and neovascularization, induces cell differentiation, inhibits cancer metastasis and invasion, and enhances chemotherapeutic drug sensitivity through multiple kinase targets and also the Na+/K+-ATPase transporter. It also inhibits proteins of the steroid receptor coactivator family, such as SRC-1 and SRC-3 at 5nM. Bufalin has anti-inflammatory effects by modulating nuclear factor-kappaB (NF-kappaB) signaling and down-regulating inflammatory-related genes such as cyclooxygenases, lipoxygenases, inducible nitric oxide synthase (iNOS), and thereby decrease nitric oxide and prostaglandin E2 (PGE2) production.
  • SMILES
    C[C@@]12[C@@](CC[C@@H]2C3=COC(C=C3)=O)(O)[C@]4([H])CC[C@]5([H])C [C@@H](O)CC[C@]5(C)[C@@]4([H])CC1
  • Storage Instruction
    -20°C,2°C to 8°C
  • UN Number
    UN 3462
  • UNSPSC
    12352200